Wuhan Bowo Biological Technology
Developing and marketing high-quality human vaccines
About Wuhan Bowo Biological Technology
Wuhan Bowo Biological Technology Co., Ltd. (BravoVax) is a biopharmaceutical company founded in 2012 by Dr. Ke Wu and Mr. Jin Shi, specializing in the research, development, manufacturing, and marketing of human vaccines. Dr. Wu, the CEO and Chairman, holds a PhD in Immunology and has over 30 years of experience in the biotechnology industry, having successfully developed seven biological products approved by the NMPA. Mr. Shi, the Vice President, has three decades of experience in the biological products industry, with extensive expertise in quality control and management.
The company's business model is focused on the industrialization of its vaccine pipeline to serve both domestic Chinese and global markets. BravoVax aims to provide safe, effective, and affordable vaccines, with a particular focus on the needs of developing countries. Its operations are guided by cGMP standards from the NMPA, WHO, and EMA. The company has established multiple technology platforms, including those for polysaccharide-protein conjugate vaccines, adenovirus vectors, attenuated and inactivated vaccines, and recombinant proteins. Its pipeline includes a next-generation Pneumococcal Conjugate Vaccine (PCV), a multivalent Rotavirus Vaccine, a broad-spectrum Human Papillomavirus (HPV) Vaccine, a Recombinant Varicella-zoster Virus (HZV) Vaccine, and a Respiratory Syncytial Virus (RSV) vaccine.
BravoVax actively forms strategic partnerships to advance its research and development. It has entered into collaborations with international bodies like the U.S. National Institutes of Health (NIH) and Johns Hopkins University for a next-generation HPV vaccine. In 2020, the company partnered with GeoVax Labs to co-develop a COVID-19 vaccine candidate. Recognized as a "state-level high-tech enterprise," BravoVax has received honors such as being named a "Gazelle Enterprise" and is part of the "3551 Optics Valley Talent Programme."
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $28M | $110M | Zhejiang Yatai Pharmaceutical · GF Venture Capital · Shifeng Xinhui · Beizeng Assets | ↗ |
Growth signals
Latest recorded traffic for Wuhan Bowo Biological Technology is 940 monthly website visits, up 291.7% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Wuhan Bowo Biological Technology in the Wuhan ecosystem
The Wuhan Bowo Biological Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- ZPZhejiang Yatai Pharmaceutical
- GCGF Venture Capital
- SXShifeng Xinhui
- BABeizeng Assets
- CUChengda University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wuhan Bowo Biological Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wuhan Bowo Biological Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.